Recently, we reported prognostic significance of thromboxane synthase (TXAS) gene expression in invasive bladder cancer. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor metastases. In this study, using immunohistochemical analysis, we found an increased expression of TXAS protein in bladder cancer. Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells with the TXAS inhibitors furegrelate or ozagrel induced an apoptotic effect measured as an increase in caspase-3 activation and cell death, and decreased survivin expression. Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel. Molecular inhibition of TXAS expression by siRNA significantly decreased cell growth and migration. In concordance with the pharmacological data, siRNAmediated reduction of TXAS expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells. In summary, the data support a role for the thromboxane A 2 pathway in the pathogenesis of bladder cancer and the potential utility of modulation of this signaling pathway for cancer chemotherapy.
Introduction
In the United States, approximately 67 160 new cases of urothelial cancer are estimated to occur for 2007, of which 13 750 will result in death (Jemal et al., 2007) . Although 75% of all bladder cancers are initially superficial, 25% of the patients are at high risk of progression to muscle-invasive disease with a substantial risk for the development of distant metastases. Radical cystectomy remains the standard of care for the muscleinvasive disease (Stein et al., 2001) . Systemic chemotherapy with cisplatin-based combinations is considered an effective treatment for patients with metastatic bladder cancer (Calabro and Sternberg, 2002) . However, the efficacy of cisplatin in bladder cancer treatment is limited by the development of drug resistance.
Paclitaxel is a widely used anticancer drug with demonstrated activity in epithelial cell solid tumors including bladder cancers (Bokemeyer et al., 1998) . Cisplatin mediates its cytotoxic effect by cross-linking DNA, disrupts the S phase of the cell cycle and induces DNA damage. Paclitaxel affects mitosis (M phase) by premature stabilization and resultant inhibition of depolymerization of the microtubule assembly (Schiff et al., 1979) . Although paclitaxel is one of the most successfully used chemotherapeutic agents, the success rate for previously untreated bladder cancer patients is 40-50%. Therefore, novel therapeutic combinations are needed.
Thromboxane synthase (TXAS) is an enzyme in the arachidonic acid pathway that catalyses the conversion of prostaglandin H 2 to thromboxane A 2 (TXA 2 ). During molecular profiling of bladder cancer, we found that TXAS is overexpressed in both squamous cell carcinoma and transitional cell carcinoma (TCC) of the bladder (Moussa et al., 2005) . Significantly, increased TXAS expression in patients with bladder cancer is negatively correlated with survival (Moussa et al., 2005) . TXAS-specific inhibitors have been shown to suppress growth and reduce the migration and invasion of bladder cancer cells (Moussa et al., 2005) . Several additional studies have shown a potential role of TXAS in promoting tumor invasion and metastases (Pradono et al., 2002; Kim et al., 2003; Nie et al., 2004; Watkins et al., 2005; Sakai et al., 2006) .
In this study, immunohistochemical studies demonstrated elevated TXAS protein expression in bladder carcinoma in situ (CIS) and cancer. TXAS inhibition increased the number of bladder cancer cells undergoing apoptosis. We also examined the effect of TXAS inhibition on bladder cancer cell sensitivity to the chemotherapeutic agents. Pharmacologic and molecular inhibition of TXAS enhanced the cytotoxicity of cisplatin and paclitaxel.
Results
Immunohistochemical demonstration of TXAS protein in invasive bladder cancer tissues To evaluate TXAS protein expression, we conducted immunohistochemical staining of human bladder tissue sections (Figure 1 ). Sections contained both non-tumor (adjacent normal) and tumor areas on the same slide protein. TXAS protein expression was found predominantly in the cytoplasm of normal epithelial cells. While adjacent normal urothelium had very low levels of TXAS expression (Figure 1a ), CIS had a moderate level of focal TXAS staining (Figure 1b ). Invasive papillary carcinoma had high levels of diffuse TXAS staining ( Figure 1c) . Interestingly, poorly differentiated highgrade cancer had intense expression (Figure 1d ). The data are representative of seven cases that showed the same pattern of expression. Increased expression of TXAS protein with tumor grade is consistent with that observed with mRNA analyses (Moussa et al., 2005) .
TXAS-specific inhibitors induce apoptosis and morphological changes in bladder cancer cells
Previous studies demonstrated that treatment of T24 and TCC-SUP bladder cancer cells with TXAS inhibitors resulted in a significant decrease in cell growth (Moussa et al., 2005) . To determine if the growth effect was in part due to an increase in apoptosis, T24 and TCC-SUP cells were treated with furegrelate or ozagrel for 12 h, and semiquantitative cell death ELISA assays measuring oligonucleosomic DNA fragments were performed. For solvent control, the mean7s.d. absorbance value was 0.01370.002 (T24) and 0.00770.001 (TCC-SUP) compared to 0.17570.028 (T24), 0.20870.028 (TCC-SUP), and 0.09570.012 (T24), 0.08670.005 (TCC-SUP) for furegrelate (1 mM) and ozagrel (2 mM), respectively (Po0.001; Figure 2a ). To examine further the apoptotic effect induced by TXAS-specific inhibitors, flow cytometric analyses were used to measure annexin-V labeling to phosphatidylserine, a membrane phospholipid exposed at the surface of apoptotic cells. After 12 h treatment with furegrelate, cells were stained with annexin-V-fluorescein isothiocyanate and propidium iodide (PI). The percentages of PI-positive cells, which indicates the fraction of cells in early apoptosis, and double positive cells, which indicate the fraction of cells in late apoptosis, were significantly higher in furegrelate-treated cells (2-and 1.8-fold for T24, and 1.5-and 2.4-fold for TCC-SUP, respectively; Po0.001 Figures 2c and d) . Total protein was extracted from treated and control cells, and activated caspase-3 was measured using an anti-caspase-3 rabbit polyclonal antibody. Treatment with furegrelate or ozagrel decreased the levels of pro-caspase-3 and increased the levels of active caspase-3 (Figure 2b) . Furthermore, the level of the antiapoptotic protein survivin is reduced in treated cells, being more pronounced after furegrelate treatment (Figure 2b ). Collectively, our analyses indicate that treatment of T24 and TCC-SUP cells with TXAS-specific inhibitors result in increased cell death.
TXAS inhibitors also reduce migration and invasion of T24 and TCC-SUP bladder cancer cells (Moussa et al., 2005) . Consistent with these observed alterations, treatment of T24 and TCC-SUP cells with the TXAS inhibitor furegrelate (1 mM) for 12 h resulted in changes in F-actin cytoskeletal organization demonstrated by phalloidin staining (Figures 2e and f) , as well as changes in cell morphology towards a less fibroblastic morphology and more rounded shape. Furthermore, exposure of the cells to furegrelate or ozagrel resulted in a decrease of total cellular F-actin and b-III tubulin levels as shown by western blot analysis (Figure 2b ).
Inhibition of TXAS activity increased bladder cancer cells sensitivity to cisplatin A common feature contributing to the failure of chemotherapy is relapse due to the acquisition of drug resistance by tumor cells in treated patients. Transitional bladder carcinoma cells may acquire cisplatin resistance through multiple pathways, including upregulation of glutathione S-transferase p, multidrug resistance-associated protein and multidrug resistance-1 (Hour et al., 2000) . In addition to these, another proposed mechanism of cisplatin resistance is the decrease of intracellular accumulation modulated by changes in Na þ -, K þ -ATPase activity (Bando et al., 1997 (Bando et al., , 1998b .
Previous studies have shown that thromboxane (TP)-receptor antagonist treatment increases Na þ -, K þ -ATPase activity along with intracellular accumulation Thromboxane synthase inhibition enhances chemosensitivity O Moussa et al and sensitivity to cisplatin in non-small cell lung cancer (Kasahara et al., 1996; Bando et al., 1998a) . Decreased Na þ -, K þ -ATPase activity was found after increased release of TXB 2 (the stable end product of TXAS) or addition of exogenous ligand (Wald et al., 1989) .
Our recent unpublished observations demonstrate that TXAS activity is increased in bladder cancer patients that could provide a mechanism for cisplatin resistance via TXA 2 -mediated decrease in Na þ -, K þ -ATPase activity.
These observations raised the possibility that using a TXAS-specific inhibitor in combination with cisplatin may enhance the sensitivity of the later. To directly explore this possibility, T24 and TCC-SUP cells were treated with solvent alone (control), or cisplatin in the absence and presence of furegrelate (1 mM) or ozagrel (2 mM). Consistent with the results presented in Figure 2 , both furegrelate and ozagrel significantly increased cell death in the absence of cisplatin. The control solvent did not have a significant effect. For T24 cells, the percentage of dead cells after combined treatment with furegrelate and 2 or 5 mg/ml cisplatin was greater than that for the sum of each treatment alone (Figure 3a) . In contrast, ozagrel failed to augment the effect of cisplatin (Figure 3a) . While TCC-SUP is more resistant to cisplatin than T24, both synthase inhibitors significantly enhanced the sensitivity of TCC-SUP to cisplatin (Figure 3c ).
Inhibition of TXAS activity increased T24 cells sensitivity to paclitaxel
Based upon the observed change in F-actin distribution and total F-actin and b-III tubulin expression after treatment with furegrelate (Figures 2b, e and f), it was possible that TXAS inhibitor would enhance the cytotoxicity of paclitaxel, which mediates its effects in large part via premature stabilization of microtubule assembly with disruption of the cytoskeletal framework. T24 and TCC-SUP cells were treated with solvent control or paclitaxel in the absence or presence of furegrelate, and the presence of dead cells assessed by Thromboxane synthase inhibition enhances chemosensitivity O Moussa et al trypan blue staining and direct cell counts. As noted for cisplatin, TCC-SUP cells are more resistant to paclitaxel. However, combined treatment of either cell line with furegrelate and paclitaxel resulted in increased cytotoxicity (Figures 3b and d) .
Effect of RNAi-mediated TXAS inhibition on cell proliferation, migration and invasion and morphology Treatment with TXAS inhibitors may have other secondary effects unrelated to inhibition of TXAS. Thus, we determined the effect of molecular inhibition of TXAS upon these phenotypes. Short hairpin RNA (shRNA) vectors to allow constitutive expression of TXAS siRNA were constructed. siRNA-mediated downregulation of TXAS resulted in >90% reduction in mRNA (data not shown) and protein expression (Figure 4a) . Consistent with the previously characterized effects observed upon pharmacological inhibition, two independent siRNA expressing T24 clones (T2 and T4) and TCC-SUP clones (T1 and T4) have significantly reduced proliferation and migration compared to control cells transfected with the GFP control vector (migration, Figure 4b ). In T24 clones T2 and T4, the reduction in cell migration was 94 and 83%, respectively, relative to cells transfected with the vector alone. For TCC-SUP clones T1 and T4, the reduction in cell migration was 71 and 86%, respectively. Molecular inhibition of TXAS by siRNA also affected cell growth, demonstrated by increased cell doubling time. While parental T24 cells have a doubling time of 22 h, siRNAexpressing clones T2 and T4 had doubling times of 84 and 60 h, respectively. While the doubling time for empty vector transfected TCC-SUP was 48 h, the doubling time for TCC-SUP clones T1 and T4 was 96 and 108 h, respectively. Morphological changes and F-actin distribution changes can be seen in T24 clone T2 and TCC-SUP clone T1 (Figure 4c ), consistent with those observed following treatment with TXAS pharmacological inhibitors. In addition to the changes in the F-actin distribution, the total cellular level of F-actin was significantly lower in cells transfected with TXAS RNAi. The level of b-III tubulin, which is associated with paclitaxel resistance, is also lower in both T24 and TCC-SUP RNAi clones compared to empty vector transfected cells (Figure 4d ).
RNAi-mediated inhibition of TXAS alters cisplatin and paclitaxel sensitivity of bladder cancer cells
We determined whether RNAi-mediated reduction of TXAS expression affected sensitivity of bladder cancer cells to cisplatin or paclitaxel. The IC 50 of cisplatin in parental T24 cells was 1.8 mg/ml, while T24 clone T4 was more sensitive, with an IC 50 of 1.0 mg/ml (Figure 5a ). For TCC-SUP control cells, the IC 50 was 36 mg/ml and was 26 mg/ml for TCC-SUP TXAS-shRNA clone T4 ( Figure 5c ). As noted above, inhibition of TXAS activity using both pharmacological and molecular approaches resulted in changes in cell morphology and cytoskeletal organization detected by phalloidin immunofluorescence staining. Based upon the observed effect of TXAS inhibition on F-actin structure, we examined the effect of reduced TXAS expression on paclitaxel cytotoxicity. The IC 50 of paclitaxel in T24 empty vector cells was significantly higher (Po0.05) 88 nM, and for clone T2, the IC 50 was 24 nM (Figure 5b) . Similar results were observed in TCC-SUP cells, the IC 50 of paclitaxel in vector control cells was 242 nM and significantly reduced to 117 nM in TCC-SUP shRNA clone T4 (Po0.05; Figure 5d ).
Discussion
This study demonstrates that inhibition of TXAS by either pharmacologic or molecular mechanisms results in an increased sensitivity to cisplatin and paclitaxel in two different bladder cancer cell lines.
The role of TXAS in tumor metastases is well documented (Giese et al., 1999; Yoshizato et al., 2002; Kim et al., 2003; Jantke et al., 2004; Moussa et al., 2005; Watkins et al., 2005) . TXAS, by virtue of catalysing the formation of TXA 2 , has previously been shown to have mitogenic and proliferative effects (Murphy et al., 1990; Pradono et al., 2002; Yoshizato et al., 2002; Kim et al., 2003; Nie et al., 2004; Moussa et al., 2005; Watkins et al., 2005; Sakai et al., 2006) . Thus, simply decreasing its synthesis may have some antiproliferative effects in cancer cells, which could result in an additive or synergistic effect on chemotherapeutic agents.
In a previous study, we demonstrated that TXASspecific inhibitors reduce cell growth, migration and invasion (Moussa et al., 2005) . These findings have been activation, and reduced survivin protein levels (Figure 2) . Thus, the modest change in total viable cell number at 12 h after treatment with furegrelate noted in the earlier study can be attributed to increased apoptosis. Several studies have reported that TP-receptor antagonists sensitize non-small lung cancer cells to cisplatin. Part of this effect may be owing to the decreased Na þ -, K þ -ATPase activity leading to diminished intracellular accumulation of the cisplatin drug into the cells after treatment (Kasahara et al., 1996; Bando et al., 1998a) . Increased levels of TXB 2 production (the stable metabolite of TXAS) is associated with the decrease in Na þ -, K þ -ATPase activity in both normal and diabetic ventricles in rat models (Pascual et al., 1988; Wald et al., 1989) . In this study, the data demonstrate that inhibition of TXAS either pharmacologically or genetically enhanced the cytotoxic effect of cisplatin. The TXAS-specific inhibitor furegrelate in combination with the cytotoxic chemotherapeutic agent cisplatin resulted in a superadditive effect on cancer cells (Figure 3 ). In contrast, ozagrel and cisplatin effects were additive, albeit at lower cisplatin concentrations. Molecular inhibition increased sensitivity, as shown by a 1.8-to 2-fold lower IC 50 . A common adverse side effect of cisplatin treatment is nephrotoxicity. For example, a single intraperitoneal injection of cisplatin (5 mg/kg) induces acute renal failure in a rat model (Winston and Safirstein, 1985) . The nephrotoxic effect of cisplatin on the kidney is thought to be mediated in part through the thromboxane A 2 pathway (Jariyawat et al., 1997) . Such a role for local TXA 2 release in the nephrotoxicity induced by cisplatin provides further support for the model that the use of TXAS inhibitors in addition to cisplatin may provide a protective effect from cisplatininduced nephrotoxicity, making these drugs excellent candidates for neoadjuvant therapy.
While pharmacological inhibition of TXAS also enhanced the cytotoxicity of paclitaxel, molecular inhibition had a more dramatic effect, decreasing the IC 50 over two-to threefold. The mechanism for augmenting paclitaxel sensitivity is due to blocking one or more effects of TXA 2 . One of the major mechanisms for tumors to develop paclitaxel resistance is the elevation of b-III tubulin (Kamath et al., 2005) . Both pharmacological and molecular inhibition of TXA 2 signaling resulted in reduction of b-III tubulin levels (Figures 2b  and 4d ), associated with increased sensitivity to the drug.
Thus, combination of current chemotherapeutic approaches with TXAS inhibitors may offer a novel therapeutic approach. Future in vivo preclinical animal studies are required to provide additional rationale for potential future clinical trials.
Materials and methods

Immunohistochemical analysis
Human bladder cancer samples were obtained from the Hollings Cancer Center Tumor Bank, MUSC. All specimens were formalin-fixed and paraffin-embedded. Antigen retrieval was performed by heating in a microwave oven for 5 min on high power in 10 mM citrate, pH 6.0. Sections were washed and nonspecific binding was blocked with 10% horse serum in Tris-buffered saline (TBS) (50 mM Tris-HCl, 0.9% NaCl, pH 8.0) for 20 min, then incubated overnight at 41C with the TXAS primary antibody (Cayman Chemicals; Ann Arbor, MI, USA) at a 1:200 dilution in the blocking solution, followed by three 10-min washes in TBS. Immpress horse anti-rabbit secondary was used (Vector Laboratories, Burlingame, CA, USA) for 45 min at room temperature. Slides were counterstained with Hematoxylin & Eosin (Fisher Scientific, Pittsburgh, PA, USA). All sections were examined independently by a clinical pathologist (M Fraig). Presence of staining was compared to that of normal bladder tissue present in the same section.
Cell culture and transfection
The bladder cancer cell lines T24 and TCC-SUP were obtained from ATCC. Cells were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) in an atmosphere containing 5% CO 2 at 371C. T24 cells were transfected with pSuppressor vector (Imgenex, San Diego, CA, USA) expressing TXAS RNAi using the ExGen 500: linear polyethylenimine (Fermentas Life Science, Hanover, MD, USA) transfection reagent. The 20-nucleotide GTTGAGAACTTCAGTAACTG 'loop' located at the position 539-558 of the ORF region of the TXAS gene (GeneBank accession no: NM_001061) used for the shRNA. Stable clones were selected in RPMI containing 400 mg/ml G418 (Invitrogen, Carlsbad, CA, USA).
Drugs
Cisplatin and paclitaxel were purchased from Sigma (St Louis, MO, USA). Stock solutions were prepared in dimethyl sulfoxide (DMSO) and stored at À201C, and were diluted to the indicated final concentration in fresh media before each experiment. In all experiments, the final DMSO concentration did not exceed 0.005%. Furegrelate and ozagrel were obtained from Cayman Chemicals; solutions were freshly prepared in phosphate-buffered saline (PBS) and diluted in RPMI medium.
IC 50 analysis T24 or TCC-SUP bladder cancer cells were cultured on 12 well plates in RPMI and allowed to grow to 70% confluence. Media were replaced with fresh media containing increasing concentrations of cisplatin or paclitaxel, alone or in combination with furegrelate or ozagrel. Cells were treated continuously for 24 h and cell viability was analysed under the microscope at 200 Â using trypan blue staining. The IC 50 was calculated using the following formulas: 50 , where (X 1 , Y 1 ) and (X 2 , Y 2 ) are two points below and above 50% cell death (X ¼ drug concentration and Y ¼ %cell death).
Morphology and cytoskeleton studies
Cell morphology and immunofluorescence analysis was performed on glass chamber slides precoated with 5 mg/ml fibronectin. Control T24, siRNA expression clone T24-T2, control TCC-SUP and TCC-SUP-T4 cells were seeded at low density (B4 cells/mm 2 ) in normal growth media and incubated for a period of 12 h. For furegrelate treatment and solvent control, cells were incubated for another 12 h with either furegrelate (1 mM) or solvent control (water). Cells were fixed with 2% formaldehyde for 10 min. After washing twice with cold PBS, cells were permeabilized with 0.1% Triton X-100. Cover slips were blocked in 2% bovine serum albumin, and actin distribution was examined by phalloidin staining as per the manufacturer's instructions (Molecular Probes, Eugene, OR, USA). Slides were examined using an Olympus Fluoview IX70 confocal microscope.
Quantitative cell death assays Cell death was measured by Cell Death detection ELISA plus (Roche Diagnostics, Penzberg, Germany) according to the manufacturer's procedure. This assay measures the cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) formed after cell death.
Annexin V PI staining and flow cytometry was used to determine early and late apoptosis, as recommended by the manufacturer (Caltag, Burlingame, CA, USA).
Western blot analysis
Total protein (40 mg) was resolved by 12% SDS-polyacrylamide gel electrophoresis and subjected to western blot analyses using Super Signal West Pico system (Pierce, Rockford, IL, USA). Western blots were probed with rabbit polyclonal antibodies against TXAS (Cayman Chemical), total and activated caspase-3, survivin, intercellular adhesion molecule 1, proliferating cell nuclear antigen, b-actin and glyceraldehyde-3-phosphate dehydrogenase (Santa-Cruz Biotechnology, CA, USA), b-III Tubulin (Chemicon, Temecula, CA, USA) and F-actin monoclonal antibody (Abcam, Cambridge, MA, USA).
Migration assay
The migration bioassay was performed as previously described (Moussa et al., 2005) . Briefly, cells were cultured to 80% confluence, then trypsinized and resuspended in serum-free medium. A total of 20 000 cells were placed in the upper compartment. Media with 10% FBS was placed in the lower compartment. After 6 h of incubation at 371C with 5% CO 2 , cells were removed from the upper compartment with cotton swabs and the membranes were fixed and stained with DiffQuik kit (Dade-Behring, Newark, DE, USA). The cells that had migrated through the membrane to the lower surface were counted under a light microscope. Each experiment was conducted in triplicate and repeated three times.
Statistical analysis
The data are presented as the mean7s.d. Statistical analyses were conducted using analysis of variance. P values o0.05 were used to reject the null hypothesis.
